HomeTerumo Corporation

Terumo Corporation

Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed’s Virtue® Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership

Under the terms of the agreement, Terumo will make a one-time, up-front payment of USD 30 million and an equity commitment of USD 5 million to Orchestra BioMed. Terumo will also make substantial future clinical and regulatory milestone payments to Orchestra BioMed.

Aortica Corporation Announces FDA Approves Medtronic Valiant NAVION™ for Inclusion in Starnes’ Physician-Sponsored IDE

12/17/18: This is an ongoing Physician Sponsored IDE study at the University of Washington sponsored by Principal Investigator & Chief of Vascular Surgery Dr. Benjamin Starnes.

Aortica™ Corp. Announces Publication of Successful Results Demonstrating Simplification of Fenestrated EVAR Using AortaFit™ Automated Case Planning Software

10/22/18: The study is an FDA approved physician-sponsored investigational device exemption (IDE) study, administered in conjunction with Harborview Medical Center and run by Dr. Benjamin Starnes, Chief of Vascular Surgery at the University of Washington (UW). Endovascular Aneurysm Repair (EVAR) is the gold standard for treatment of Abdominal Aortic Aneurysms (AAA).

Terumo BCT Announces 2016 Advancing Apheresis Award Winner; Opens Applications for 2017

5/1/17: Terumo BCT funds a $10,000 USD grant to Aarhus University Hospital for solving venous access challenges.